liafensine liafensine liafensine (bms-820836) is a serotonin-norepinephrine-dopamine reuptake inhibitor (sndri) which was under development by bristol-myers squibb for the treatment of major depressive disorder. though it demonstrated comparable effectiveness to escitalopram and duloxetine in phase ii clinical trials, development was paused in 2013 because liafensine failed to show superior effectiveness relative to these drugs, a decision that was made likely based on its increased capacity for side effects as well as potential for abuse. liafensineclinical dataroutes ofadministrationoralatc codenonelegal statuslegal status development terminated identifiers iupac name 6--3-pyridazinamine cas number1198790-53-2pubchem cid58212050chemspider29271896uniir34id086z6keggd10443comptox dashboard (epa)dtxsid60152610 chemical and physical dataformulac24h22n4molar mass366.468 g·mol−13d model (jsmol)interactive image smiles cn1c(c2=c(c1)c=c(c=c2)c3=nn=c(c=c3)n)c4=cc5=cc=cc=c5c=c4 inchi inchi=1s/c24h22n4/c1-28-14-20-13-19(23-10-11-24(25)27-26-23)8-9-21(20)22(15-28)18-7-6-16-4-2-3-5-17(16)12-18/h2-13,22h,14-15h2,1h3,(h2,25,27)/t22-/m0/s1key:vcibgdsrpuobog-qfipxvfzsa-n